0000000000672701

AUTHOR

Sara Tenti

showing 2 related works from this author

Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results fro…

2022

Abstract Objective To evaluate the efficacy of prescription-grade Crystalline Glucosamine Sulfate (pCGS) as an add-on treatment to conventional therapy, compared to usual therapy alone, in patients with erosive osteoarthritis of the hand (EHOA). Methods This 6-month retrospective case–control study included patients with concomitant knee osteoarthritis and symptomatic EHOA. Participants were stratified into two groups based on whether or not pCGS (1500 mg/day) was added to the conventional therapy (education and training in ergonomic principles, exercise and use on-demand of symptomatic drugs) for hand osteoarthritis. Patients were evaluated at baseline, after 3 and 6 months. Primary outcom…

AgingGlucosamineSymptomatic slow-acting drugs for osteoarthritisPainOsteoarthritis KneePrescription-grade crystalline glucosamine sulfateErosive hand osteoarthritis; Hand osteoarthritis; Pain; Prescription-grade crystalline glucosamine sulfate; Retrospective study; Symptomatic slow-acting drugs for osteoarthritisErosive hand osteoarthritisRetrospective studyPrescriptionsTreatment OutcomeCase-Control StudiesHand osteoarthritisHumansErosive hand osteoarthritis Hand osteoarthritis Pain Prescription-grade crystalline glucosamine sulfate Retrospective study Symptomatic slow-acting drugs for osteoarthritisGeriatrics and GerontologyRetrospective StudiesAging clinical and experimental research
researchProduct

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteo…

2021

This study investigated the possible anti-inflammatory and chondroprotective effects of a combination of celecoxib and prescription-grade glucosamine sulfate (GS) in human osteoarthritic (OA) chondrocytes and their possible mechanism of action. Chondrocytes were treated with celecoxib (1.85 µM) and GS (9 µM), alone or in combination with IL-1β (10 ng/mL) and a specific nuclear factor (NF)-κB inhibitor (BAY-11-7082, 1 µM). Gene expression and release of some pro-inflammatory mediators, metalloproteinases (MMPs), and type II collagen (Col2a1) were evaluated by qRT-PCR and ELISA

Interleukin-1betachondrocytesAnti-Inflammatory AgentsApoptosisPharmacologymedicine.disease_causeNF-κBchemistry.chemical_compoundchondroprotectionoxidative stressSulfonesBiology (General)SpectroscopyCells CulturedGlucosamineglucosamine sulfatebiologycelecoxibChemistrySuperoxideNF-kappa BGeneral MedicineComputer Science ApplicationsChemistrychondrocyteosteoarthritiDrug Therapy Combinationmedicine.symptomInflammation Mediatorsmedicine.drugSignal TransductionNF-BQH301-705.5Cell SurvivalGlucosamine SulfateCatalysisArticleInorganic ChemistrySuperoxide dismutaseNitrilesOsteoarthritismedicineHumansPhysical and Theoretical ChemistryQD1-999Molecular Biologyoxidative streOrganic ChemistryMechanism of actionApoptosisinflammationbiology.proteinCelecoxibCyclooxygenaseOxidative stressInternational Journal of Molecular Sciences
researchProduct